Your browser is no longer supported. Please, upgrade your browser.
Settings
VBIV VBI Vaccines Inc. daily Stock Chart
VBIV [NASD]
VBI Vaccines Inc.
Index- P/E- EPS (ttm)-0.35 Insider Own5.26% Shs Outstand230.65M Perf Week6.06%
Market Cap484.36M Forward P/E- EPS next Y-0.77 Insider Trans299.84% Shs Float150.32M Perf Month69.35%
Income- PEG- EPS next Q-0.22 Inst Own44.45% Short Float5.42% Perf Quarter61.54%
Sales2.28M P/S212.81 EPS this Y0.00% Inst Trans- Short Ratio0.89 Perf Half Y142.86%
Book/sh0.42 P/B5.04 EPS next Y12.50% ROA- Target Price- Perf Year22.81%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range0.47 - 2.98 Perf YTD52.17%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-29.53% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low351.13% ATR0.27
Employees123 Current Ratio- Sales Q/Q15.30% Oper. Margin- RSI (14)56.73 Volatility12.25% 16.40%
OptionableYes Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.73 Prev Close2.02
ShortableYes LT Debt/Eq- EarningsMar 02 Payout- Avg Volume9.20M Price2.10
Recom1.50 SMA205.20% SMA5043.84% SMA20097.49% Volume6,711,088 Change3.96%
Jan-16-19Initiated Oppenheimer Outperform $9
Nov-01-17Initiated Canaccord Genuity Buy $10
Oct-10-16Initiated Laidlaw Buy $6
Jul-26-16Initiated Ladenburg Thalmann Buy
May-07-15Initiated Noble Financial Buy $7
Jun-04-20 07:06PM  
May-28-20 08:00AM  
May-27-20 08:00AM  
May-21-20 09:22AM  
May-20-20 08:35AM  
May-15-20 08:00AM  
May-11-20 08:16AM  
May-06-20 05:13PM  
09:15AM  
08:00AM  
Apr-29-20 12:34PM  
Apr-28-20 11:38AM  
Apr-27-20 08:00AM  
Apr-22-20 09:12AM  
07:51AM  
Apr-21-20 04:05PM  
Apr-20-20 08:49AM  
Apr-13-20 08:58AM  
Apr-01-20 09:04AM  
Mar-31-20 08:00AM  
Mar-12-20 11:39AM  
11:23AM  
08:00AM  
Mar-05-20 09:15AM  
08:00AM  
Mar-03-20 08:00AM  
Mar-02-20 08:00AM  
Feb-17-20 12:30PM  
Feb-05-20 02:45PM  
Jan-31-20 11:14AM  
Jan-27-20 09:17AM  
Jan-14-20 08:00AM  
Jan-09-20 08:56AM  
08:47AM  
08:00AM  
Jan-07-20 02:31PM  
10:00AM  
08:30AM  
Dec-16-19 07:52AM  
Nov-25-19 08:56AM  
Nov-22-19 08:18AM  
08:00AM  
Nov-21-19 11:32AM  
Nov-20-19 01:28PM  
Nov-17-19 08:42AM  
Nov-14-19 08:00AM  
Nov-11-19 08:00AM  
Nov-06-19 09:25AM  
08:00AM  
Nov-04-19 08:44AM  
Nov-01-19 10:30AM  
Oct-29-19 07:32AM  
Oct-27-19 12:56PM  
Oct-24-19 08:00AM  
Oct-22-19 08:00AM  
Oct-14-19 08:36AM  
Oct-06-19 08:22PM  
Oct-02-19 08:00AM  
Oct-01-19 08:10AM  
Sep-26-19 08:00AM  
Sep-24-19 09:04AM  
Sep-19-19 09:00AM  
Sep-18-19 04:01PM  
Sep-10-19 07:00AM  
Sep-04-19 08:58AM  
Aug-15-19 09:57AM  
Aug-09-19 09:15AM  
08:00AM  
Aug-05-19 08:00AM  
Jul-29-19 08:00AM  
Jul-18-19 10:32AM  
09:00AM  
Jul-01-19 08:00AM  
Jun-20-19 08:00AM  
Jun-19-19 03:15PM  
Jun-17-19 06:33AM  
06:09AM  
06:00AM  
Jun-16-19 12:00PM  
Jun-13-19 05:00PM  
Jun-06-19 04:22AM  
Jun-04-19 08:00AM  
May-06-19 09:00AM  
May-01-19 01:16PM  
08:00AM  
Apr-30-19 10:32AM  
Apr-23-19 08:00AM  
Apr-18-19 07:26AM  
Apr-17-19 08:00AM  
Apr-11-19 04:05PM  
Apr-03-19 08:00AM  
Mar-18-19 08:00AM  
Feb-25-19 08:00AM  
Feb-07-19 08:00AM  
Jan-16-19 08:00AM  
Dec-20-18 08:00AM  
Dec-18-18 08:00AM  
Dec-13-18 09:05AM  
Dec-12-18 04:01PM  
Dec-06-18 08:00AM  
VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology in Israel, the United States, and internationally. The company offers Sci-B-Vac, a prophylactic hepatitis B vaccine for adults, children, and newborns. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for a functional cure of chronic hepatitis B. The company's enveloped virus-like particle (eVLP) platform technology allows for the development of eVLP vaccines that mimic the target virus to elicit a potent immune response. Its lead eVLP program candidates include VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study; and VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial. In addition, the company engages in the development of vaccine platforms and products for licensing to pharmaceutical companies and biotechnology companies. It primarily serves physicians and pharmacists through direct sales. VBI Vaccines Inc. has collaboration and license agreements with Brii Biosciences Limited; and GlaxoSmithKline Biologicals S.A. It also has a collaboration with the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
PERCEPTIVE ADVISORS LLC10% OwnerApr 24Buy1.109,090,90910,000,00055,042,456Apr 28 09:00 AM
Diaz-Mitoma FranciscoChief Medical OfficerOct 04Buy0.5040,00020,000117,500Oct 07 11:35 AM
Beattie NellChief Business OfficerOct 01Buy0.4810,0004,82260,000Oct 01 12:39 PM
McNulty ChristopherCFO and Head of BDOct 01Buy0.4712,0005,67637,000Oct 01 12:39 PM
Baxter JeffCEO, PresidentSep 30Buy0.50150,00075,450608,255Sep 30 04:22 PM
Diaz-Mitoma FranciscoChief Medical OfficerSep 30Buy0.5014,5007,25014,500Oct 07 11:35 AM
PERCEPTIVE ADVISORS LLC10% OwnerSep 23Buy0.5020,000,00010,000,00045,951,556Sep 24 06:30 PM
Diaz-Mitoma FranciscoChief Medical OfficerJun 27Buy1.078,0008,56077,500Jul 01 06:10 AM
Diaz-Mitoma FranciscoChief Medical OfficerJun 20Buy0.8752,00045,18069,500Jun 20 03:59 PM
Beattie NellChief Business OfficerJun 19Buy0.748,0005,88650,000Jun 19 12:20 PM
Baxter JeffCEO, PresidentJun 19Buy0.73144,000105,336458,255Jun 19 12:17 PM
PERCEPTIVE ADVISORS LLC10% OwnerJun 18Buy0.651,000,000650,00025,951,556Jun 20 10:19 AM
PERCEPTIVE ADVISORS LLC10% OwnerJun 17Buy0.621,000,000618,00024,951,556Jun 18 11:10 AM